Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma.

ABSTRACT: Extranodal marginal zone lymphoma (EMZL) is a heterogeneous disease with a subset of patients exhibiting a more aggressive course. We previously reported that EMZL with multiple mucosal sites (MMS) at diagnosis is characterized by shorter survival. To better recognize patients with different patterns of progression-free survival (PFS) we developed and validated a new prognostic index primarily based on patient's disease characteristics. We derived the "Revised mucosa-associated lymphoid tissue International Prognostic Index" (Revised MALT-IPI) in a large data set (n = 397) by identifying candidate variables that showed highest prognostic association with PFS. The revised MALT-IPI was validated in two independent cohorts, from the University of Iowa/Mayo Clinic (n = 297) and from IELSG-19 s

SUBMITTER: Alderuccio JP 

PROVIDER: S-EPMC9847507 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature